WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on reports of the retirement of Richard Pazdur from the US FDA ...

WASHINGTON, DC (December 2, 2025) – The Biotechnology Innovation Organization (BIO), in partnership with the Council of State Bioscience Associations (CSBA), released today its latest biennial report ...

How the BIO IP Conference moved the conversation forward. Also, patient perspectives on diabetes innovation. (761 words, 3 minutes, 48 seconds) BIO IP Conference covers present and future of patent ...

WASHINGTON, D.C. – The Biotechnology Innovation Organization (BIO) released the following statement on today’s passage of the Mikaela Naylon Give Kids a Chance Act in the House of Representatives.

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, ...

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on the potential for 100% tariffs on branded or patented ...

Collaboration maximizes BIO members’ access to Avantor’s market-leading portfolio of products, materials, and services to accelerate scientific innovation. WASHINGTON, D.C., September 17, 2025 - The ...

It's Day 4. We recap a few impactful sessions exploring why patients – including rare disease patients and women – can't wait. Today, we close out with a look at how we can ensure the virtuous cycle ...

WASHINGTON, D.C. - John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding today’s dismissal of the voting members of the CDC ...

Washington, DC, May 28, 2025 – The Biotechnology Innovation Organization (BIO) today announced plans to dedicate its focus entirely to human health and to transition the work of its Agriculture and ...

“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the ...

BIO launches a new campaign to explain why we vaccinate – and why it's good for America. We have details, plus how drug companies are investing in U.S. manufacturing, news on drug prices and IP, and ...